Mobile website
Archive > Volume 24 Issue 2 > 2017,24(2):174-179. DOI:10.3872/j.issn.1007-385X.2017.02.012 Prev Next
Clinical Research
Analysis of clinical efficacy and prognosis of DC-CIK cellular immunotherapy in with gastric cancer
- Article
- Figures
- Metrics
- Preview PDF
- Reference
- Related
- Cited by
- Materials
Abstract:
Objective:To retrospectively analyze safety and clinical efficacy of dendritic cells (DCs) combined with cytokine-induced killer (CIK) cellular immunotherapy in treatment of the 96 patients with gastric cancer (GC). Methods: Peripheral blood mononuclear cells (PBMCs) from the 96 GC patients who were hospitalized in the Oncology Department of the 86th Hospital of PLA and Tumor Biotherapy Center of the 81st Hospital of PLA during August 2011 to April 2016 were collected and cultured ex vivo to obtain DC and CIK cells. After sensitization with gastric cancer MGC-803 line cell lysates, the DCs combined with CIK cells were transfused back to the GC patients. Clinical efficacy and safety of the DC-CIK cellular immunotherapy were observed. Results: Overall response rate and disease control rate of the 96 GC patients following the DC-CIK immunotherapy were 15.6% and 55.2% respectively. Their 1 year survival rate was 56.0%, whereas rate of overall survival for 36-56 months was maintained at about 37.0%. No significant difference was observed in peripheral blood value of tumor markers, CEA, CA199 and CA724 of the GC patients between pretherapy and postherapy. After the DC-CIK immunotherapy the percentage of CD4+CD25+ Treg cell in peripheral blood of the GC patients was significantly decreased (\[3.22±1.20\]% vs \[2.46±1.04\]%, P<0.01), but the percentages of CD3+, CD4+, CD8+ and CD3+CD56+ T cell subsets as well as ratio of CD4+/CD8+ did not show any significant changes (P>0.05). Kaplan-Meier univariate analysis showed that TEM staging, times of the cellular immunotherapy as well as pretherapy value of CEA and CA199 were influence factors for prognosis of the GC patients treated with the DC-CIK cellular immunotherapy. Multivariate analysis with Cox model further indicated that times of the cellular immunotherapy as well as pretherapy value of CEA and CA199 were significantly associated with prognosis of the GC patients treated with the DC-CIK cellular immunotherapy (P<0.05). Conclusion: Autologous DC-CIK immunotherapy might be a safe and efficacy therapy approach for the GC patients, however multiple therapy of the DC-CIK immunotherapy could improve long-term survival rate of the patients with GC.
Keywords:
Project Supported:
Project supported by the General Program of Nanjing Military Region（No.15ms 077）
Clc Number:
